{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T03:29:41Z","timestamp":1788838181722,"version":"build-2803163510"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T00:00:00Z","timestamp":1543449600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Forensic Sci Med Pathol"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s12024-018-0049-9","type":"journal-article","created":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T00:41:42Z","timestamp":1543452102000},"page":"110-113","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Fatal combination of mitragynine and quetiapine \u2013 a case report with discussion of a potential herb-drug interaction"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7422-0346","authenticated-orcid":false,"given":"Rhome L.","family":"Hughes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,29]]},"reference":[{"key":"49_CR1","first-page":"2421","volume":"9","author":"S Trakulsrichai","year":"2015","unstructured":"Trakulsrichai S, Sathirakul K, Auparakkitanon S, Krongvorakul J, Sueajai J, Noumjad N, et al. Pharmacokinetics of mitragynine in man. Drug Des Devel Ther. 2015;9:2421\u20139.","journal-title":"Drug Des Devel Ther"},{"key":"49_CR2","first-page":"792","volume":"112","author":"W Prozialeck","year":"2012","unstructured":"Prozialeck W, Jivan J, Andurkar S. Pharmacology of kratom: an emerging botanical agent with stimulant, analgesic and opioid-like effects. J Am Osteopath Assoc. 2012;112:792\u20139.","journal-title":"J Am Osteopath Assoc"},{"key":"49_CR3","doi-asserted-by":"publisher","first-page":"580","DOI":"10.3390\/ijms17040580","volume":"17","author":"F Pantano","year":"2016","unstructured":"Pantano F, Tittarelli R, Mannocchi G, Zaami S, Ricci S, Giorgetti R, et al. Hepatotoxicity induced by \u201cthe 3Ks\u201d: kava, kratom and khat. Int J Mol Sci. 2016;17:580.","journal-title":"Int J Mol Sci"},{"key":"49_CR4","unstructured":"Kratom (Mitragyna speciosa korth). 2013. \n                    http:\/\/www.deadiversion.usdoj.gov\/drug_chem_info\/kratom.pdf\n                    \n                  . Accessed 7 July 2016."},{"key":"49_CR5","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1080\/08998280.2017.11929647","volume":"30","author":"A Castillo","year":"2017","unstructured":"Castillo A, Payne JD, Nugent K. Posterior reversible leukoencephalopathy syndrome after kratom ingestion. Proc (Baylor Univ Med Cent). 2017;30:355\u20137.","journal-title":"Proc (Baylor Univ Med Cent)"},{"key":"49_CR6","first-page":"49","volume":"115","author":"D Galbis-Reig","year":"2016","unstructured":"Galbis-Reig D. A case report of kratom addiction and withdrawal. WMJ. 2016;115:49\u201352.","journal-title":"WMJ"},{"key":"49_CR7","unstructured":"Food and Drug Administration. 2018. Statement for FDA Commissioner Scott Gottlieb, M.D., on the agency\u2019s scientific evidence on the presence of opioid compounds in kratom, underscoring its potential for abuse [Press release]. \n                    https:\/\/www.fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm595622.htm\n                    \n                  . Accessed 2 Aug 2018."},{"key":"49_CR8","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1177\/1751143717712652","volume":"19","author":"G Aggarwal","year":"2018","unstructured":"Aggarwal G, Robertson E, McKinlay J, Walter E. Death from kratom toxicity and the possible role of intralipid. J Intensive Care Soc. 2018;19:61\u20133.","journal-title":"J Intensive Care Soc"},{"key":"49_CR9","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.forsciint.2016.12.020","volume":"271","author":"O Domingo","year":"2017","unstructured":"Domingo O, Roider G, Stover A, Graw M, Musshoff F, Sachs H, et al. Mitragynine concentrations in two fatalities. Forensic Sci Int. 2017;271:e1\u20137.","journal-title":"Forensic Sci Int"},{"key":"49_CR10","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s00414-015-1279-y","volume":"130","author":"ML Warner","year":"2016","unstructured":"Warner ML, Kaufman NC, Grundmann O. The pharmacology and toxicology of kratom: from traditional herb to drug of abuse. Int J Legal Med. 2016;130:127\u201338.","journal-title":"Int J Legal Med"},{"key":"49_CR11","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1007\/s13181-010-0079-5","volume":"6","author":"JL Nelsen","year":"2010","unstructured":"Nelsen JL, Lapoint J, Hodgman MJ, Aldous KM. Seizure and coma following kratom (mitragynine speciosa korth) exposure. J Med Toxicol. 2010;6:424\u20136.","journal-title":"J Med Toxicol"},{"key":"49_CR12","volume-title":"Disposition of toxic drugs and chemicals in man","author":"RC Baselt","year":"2008","unstructured":"Baselt RC. Disposition of toxic drugs and chemicals in man. 8th ed. Foster City (CA): Biomedical Publications; 2008.","edition":"8"},{"key":"49_CR13","volume-title":"Handbook of forensic toxicology for medical examiners","author":"DK Molina","year":"2010","unstructured":"Molina DK. Handbook of forensic toxicology for medical examiners. Boca Raton: CRC Press; 2010."},{"key":"49_CR14","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1345\/aph.1L371","volume":"43","author":"JS Gortney","year":"2009","unstructured":"Gortney JS, Fagan A, Kissack JC. Neuroleptic malignant syndrome secondary to quetiapine. Ann Pharmacother. 2009;43:785\u201391.","journal-title":"Ann Pharmacother"},{"key":"49_CR15","volume-title":"Kratom and other mitragynines: the chemistry and pharmacology of opioids from a non-opium source","author":"RB Raffa","year":"2015","unstructured":"Raffa RB. Kratom and other mitragynines: the chemistry and pharmacology of opioids from a non-opium source. Boca Raton: CRC Press; 2015."},{"key":"49_CR16","doi-asserted-by":"publisher","first-page":"599","DOI":"10.3109\/15563659809028056","volume":"36","author":"TJ Harmon","year":"1998","unstructured":"Harmon TJ, Benitez JG, Krenzelok EP, Cortes-Belen E. Loss of consciousness from acute quetiapine overdosage. J Toxicol Clin Toxicol. 1998;36:599\u2013602.","journal-title":"J Toxicol Clin Toxicol"},{"key":"49_CR17","doi-asserted-by":"publisher","first-page":"509","DOI":"10.2165\/00003088-200140070-00003","volume":"40","author":"CL Devane","year":"2001","unstructured":"Devane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet. 2001;40:509\u201322.","journal-title":"Clin Pharmacokinet"},{"key":"49_CR18","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1124\/dmd.108.023291","volume":"37","author":"GV Bakken","year":"2009","unstructured":"Bakken GV, Rudberg I, Christensen H, Molden E, Refsum H, Hermann M. Metabolism of quetiapine by CYP3A4 and CYP3A5 in presence or absence of cytochrome B5. Drug Metab Dispos. 2009;37:254\u20138.","journal-title":"Drug Metab Dispos"},{"key":"49_CR19","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/j.1365-2125.2005.02507.x","volume":"61","author":"SW Grimm","year":"2006","unstructured":"Grimm SW, Richtand NM, Winter HR, Stams KR, Reele SB. Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. Br J Clin Pharmacol. 2006;61:58\u201369.","journal-title":"Br J Clin Pharmacol"},{"key":"49_CR20","first-page":"241","volume":"5","author":"NA Hanapi","year":"2013","unstructured":"Hanapi NA, Ismail S, Mansor SM. Inhibitory effect of mitragynine on human cytochrome P450 enzyme activities. Pharm Res. 2013;5:241\u20136.","journal-title":"Pharm Res"},{"key":"49_CR21","first-page":"391","volume":"76","author":"T Lynch","year":"2007","unstructured":"Lynch T, Price A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician. 2007;76:391\u20136.","journal-title":"Am Fam Physician"},{"key":"49_CR22","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1515\/DMDI.2006.21.3-4.187","volume":"21","author":"J Hasselstrom","year":"2006","unstructured":"Hasselstrom J, Linnet K. In vitro studies on quetiapine metabolism using the substrate depletion approach with focus on drug-drug interactions. Drug Metabol Drug Interact. 2006;21:187\u2013211.","journal-title":"Drug Metabol Drug Interact"},{"key":"49_CR23","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.bcp.2015.01.008","volume":"94","author":"MR Meyer","year":"2015","unstructured":"Meyer MR, Wagmann L, Schneider-Daum N, Loretz B, de Souza Carvalho C, Lehr CM, et al. P-glycoprotein interactions of novel psychoactive substances \u2013 stimulation of ATP consumption and transport across Caco-2 monolayers. Biochem Pharmacol. 2015;94:220\u20136.","journal-title":"Biochem Pharmacol"},{"key":"49_CR24","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.pbb.2012.04.002","volume":"102","author":"U Schmitt","year":"2012","unstructured":"Schmitt U, Kirschbaum KM, Poller B, Kusch-Poddar M, Drewe J, Hiemke C, et al. In vitro p-glycoprotein efflux inhibition by atypical antipsychotics is in vivo nicely reflected by pharmacodynamic but less by pharmacokinetic changes. Pharmacol Biochem Behav. 2012;102:312\u201320.","journal-title":"Pharmacol Biochem Behav"}],"container-title":["Forensic Science, Medicine and Pathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12024-018-0049-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12024-018-0049-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12024-018-0049-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T19:24:21Z","timestamp":1574969061000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12024-018-0049-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,29]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["49"],"URL":"https:\/\/doi.org\/10.1007\/s12024-018-0049-9","relation":{},"ISSN":["1547-769X","1556-2891"],"issn-type":[{"value":"1547-769X","type":"print"},{"value":"1556-2891","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,29]]},"assertion":[{"value":"5 November 2018","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2018","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}